POST-COVID-19 MUCORMYCOSIS: A CROSS-SECTIONAL STUDY AT A GOVERNMENT MEDICAL COLLEGE HOSPITAL IN CENTRAL REGION OF INDIA

Main Article Content

Dipti R. Wadhwani
Ritesh B. Wadhwani

Keywords

COVID-19, mucormycosis, Diabetes mellitus, maxillectomy, obturator

Abstract

Background: The surge in cases of COVID-19 in India during the second wave of the pandemic was associated with increased reporting of invasive mucormycosis. The most common type was rhino-orbito-cerebral mucormycosis, with many cases showing involvement of palate and maxilla. Management included antifungal therapy and aggressive surgical debridement, with maxillectomy performed in many patients.


Materials and Methods: A cross‑sectional analytical study was performed in department of Dentistry at a Government Medical College Hospital in central region of India. A total of 108 cases of post-COVID-19 mucormycosis were included in the study. Complete case history including the treatment received for COVID‑19, presence of any co-morbidity, imaging findings and histopathological findings were recorded. Presence of oral findings pertinent to mucormycosis were recorded. Data was collected regarding treatment received by the patients.


Results: 77 (71.3%) patients were males and 31 (28.7%) patients were females. 79 (73.1%) patients had Diabetes mellitus as co-morbidity. 69 (63.9%) patients received inhalational oxygen therapy, 82 (75.9%) patients received injection steroid and 52 (48.1%) patients received injection remdesivir. 71 (65.7%) patients showed presence of oral manifestations of mucormycosis. 33 (30.6%) patients had multiple draining sinuses over periodontium, 51 (47.2%) patients had swelling/ulcer/black eschar/bone exposure over palate or maxillary/mandibular bone and 59 (54.6%) patients showed pain/mobility/tenderness of teeth. All the patients received systemic anti-fungal therapy. Functional endoscopic sinus surgery (FESS) was performed in 105 patients. 55 patients underwent maxillectomy and two patients underwent endoscopic maxillectomy. Three patients underwent marginal mandibulectomy. Prosthetic obturator with complete/partial denture was fabricated for 14 patients.

Abstract 62 | Pdf Downloads 50

References

1. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020; 91(1):157-160.
2. Sarkar A, Chakrabarti AK, Dutta S. Covid-19 Infection in India: A Comparative Analysis of the Second Wave with the First Wave. Pathogens. 2021 Sep 21;10(9):1222. doi: 10.3390/pathogens10091222. PMID: 34578254; PMCID: PMC8469101.
3. Steinbrink JM, Miceli MH. Mucormycosis. Infect Dis Clin North Am. 2021 Jun;35(2):435-452. doi: 10.1016/j.idc.2021.03.009. PMID: 34016285; PMCID: PMC10110349.
4. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012 Feb;54 Suppl 1:S23-34. doi: 10.1093/cid/cir866. PMID: 22247442.
5. Richardson M. The ecology of the Zygomycetes and its impact on environmental exposure. Clin Microbiol Infect. 2009 Oct;15 Suppl 5:2-9. doi: 10.1111/j.1469-0691.2009.02972.x. PMID: 19754749.
6. Bhatt K, Agolli A, Patel MH, Garimella R, Devi M, Garcia E, Amin H, Domingue C, Guerra Del Castillo R, Sanchez-Gonzalez M. High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections. Discoveries (Craiova). 2021 Mar 31;9(1):e126. doi: 10.15190/d.2021.5. PMID: 34036149; PMCID: PMC8137279.
7. Pillsbury HC, Fischer ND. Rhinocerebral mucormycosis. Arch Otolaryngol. 1977 Oct;103(10):600-4. doi: 10.1001/archotol.1977.00780270068011. PMID: 907563.
8. Azhar A, Khan WH, Khan PA, Alhosaini K, Owais M, Ahmad A. Mucormycosis and COVID-19 pandemic: Clinical and diagnostic approach. J Infect Public Health. 2022 Apr;15(4):466-479. doi: 10.1016/j.jiph.2022.02.007. Epub 2022 Feb 18. PMID: 35216920; PMCID: PMC8855610.
9. Steinbrink JM, Miceli MH. Mucormycosis. Infect Dis Clin North Am. 2021 Jun;35(2):435-452. doi: 10.1016/j.idc.2021.03.009. PMID: 34016285; PMCID: PMC10110349.
10. Mattingly JK, Ramakrishnan VR. Rhinocerebral Mucormycosis of the Optic Nerve. Otolaryngol Head Neck Surg. 2016 Nov;155(5):888-889. doi: 10.1177/0194599816658024. Epub 2016 Jun 28. PMID: 27352893.
11. World Health Organization. Emergencies, coronavirus-disease (COVID-19), mucormycosis, Fact sheet. Available from: https://www.who.int/india/emergencies/ coronavirus-disease-(covid-19)/mucormycosis
12. Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin Infect Dis. 2012 Feb;54 Suppl 1(Suppl 1):S16-22. doi: 10.1093/cid/cir865. PMID: 22247441; PMCID: PMC3286196.
13. Ahmed E, Abou-Bakr A, Hussein RR, El-Gawish AA, Ras AE, Ghalwash DM. Oral mucormycosis in post-COVID-19 patients: A case series. Oral Dis. 2022 Nov;28 Suppl 2:2591-2592. doi: 10.1111/odi.13973. Epub 2021 Aug 20. PMID: 34289206; PMCID: PMC8447017.
14. Somkuwar S, Vijayabharathi P, Galhotra V, Rao S, Nagarkar NM, Raghani M, Pathak VK, Mehta R. Clinical, Demographic, and Oral Presentations of COVID-19 Associated Mucormycosis from a Tertiary Care Hospital in India: A Cross-Sectional Study. J Maxillofac Oral Surg. 2023 Dec;22(4):1130-1138. doi: 10.1007/s12663-023-01970-z. Epub 2023 Jul 11. PMID: 38105823; PMCID: PMC10719169.
15. Raghani M, Md Nasimuddin Ansari H, Hafeez A A, Agarwal S. Post-COVID Mucormycosis Involving Mandible: A Rare Phenomenon. Cureus. 2023 Jan 27;15(1):e34260. doi: 10.7759/cureus.34260. PMID: 36860215; PMCID: PMC9969176.
16. Janjua OS, Shaikh MS, Fareed MA, Qureshi SM, Khan MI, Hashem D, Zafar MS. Dental and Oral Manifestations of COVID-19 Related Mucormycosis: Diagnoses, Management Strategies and Outcomes. J Fungi (Basel). 2021 Dec 31;8(1):44. doi: 10.3390/jof8010044. PMID: 35049983; PMCID: PMC8781413.
17. Pathak L, Tripathi A, Nayyar SS, Kurkure R, Yadav A, Mishra J, Das B, Tiwari S. Management of post-COVID mucormycosis at a tertiary care center in Northern India. Egypt J Otolaryngol. 2023;39(1):19. doi: 10.1186/s43163-023-00388-1. Epub 2023 Jan 23. PMCID: PMC9869295.
18. Aranjani JM, Manuel A, Abdul Razack HI, Mathew ST. COVID-19-associated mucormycosis: Evidence-based critical review of an emerging infection burden during the pandemic's second wave in India. PLoS Negl Trop Dis. 2021 Nov 18;15(11):e0009921. doi: 10.1371/journal.pntd.0009921. PMID: 34793455; PMCID: PMC8601521.
19. Satish D, Joy D, Ross A, Balasubramanya. Mucormycosis coinfection associated with global COVID-19: a case series from India. Int J Otorhinolaryngol Head Neck Surg 2021;7:815-20.
20. Manda VV, Patruni M, Nagendra MB, Bharthi MS, Nagappa V, Kurumella HS. Epidemiology of mucormycosis in post-COVID-19 patients treated in a tertiary care hospital, Visakhapatnam, Andhra Pradesh. J Family Med Prim Care. 2022 Nov;11(11):6995-7000. doi: 10.4103/jfmpc.jfmpc_935_22. Epub 2022 Dec 16. PMID: 36993057; PMCID: PMC10041281.
21. Gebremariam T, Alkhazraji S, Alqarihi A, Wiederhold NP, Najvar LK, Patterson TF, Filler SG, Ibrahim AS. Evaluation of Sex Differences in Murine Diabetic Ketoacidosis and Neutropenic Models of Invasive Mucormycosis. J Fungi (Basel). 2021 Apr 18;7(4):313. doi: 10.3390/jof7040313. PMID: 33919611; PMCID: PMC8072604.
22. Prakash H, Ghosh AK, Rudramurthy SM, Singh P, Xess I, Savio J, Pamidimukkala U, Jillwin J, Varma S, Das A, Panda NK, Singh S, Bal A, Chakrabarti A. A prospective multicenter study on mucormycosis in India: Epidemiology, diagnosis, and treatment. Med Mycol. 2019 Jun 1;57(4):395-402. doi: 10.1093/mmy/myy060. PMID: 30085158.
23. Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr. 2021 Jul-Aug;15(4):102146. doi: 10.1016/j.dsx.2021.05.019. Epub 2021 May 21. PMID: 34192610; PMCID: PMC8137376.
24. John TM, Jacob CN, Kontoyiannis DP. When Uncontrolled Diabetes Mellitus and Severe COVID-19 Converge: The Perfect Storm for Mucormycosis. J Fungi (Basel). 2021 Apr 15;7(4):298. doi: 10.3390/jof7040298. PMID: 33920755; PMCID: PMC8071133.
25. Bala K, Chander J, Handa U, Punia RS, Attri AK. A prospective study of mucormycosis in north India: experience from a tertiary care hospital. Med Mycol. 2015 Apr;53(3):248-57. doi: 10.1093/mmy/myu086. Epub 2015 Jan 13. PMID: 25587084.
26. Patel A, Kaur H, Xess I, Michael JS, Savio J, Rudramurthy S, Singh R, Shastri P, Umabala P, Sardana R, Kindo A, Capoor MR, Mohan S, Muthu V, Agarwal R, Chakrabarti A. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect. 2020 Jul;26(7):944.e9-944.e15. doi: 10.1016/j.cmi.2019.11.021. Epub 2019 Dec 4. PMID: 31811914.
27. Al-Tawfiq JA, Alhumaid S, Alshukairi AN, Temsah MH, Barry M, Al Mutair A, Rabaan AA, Al-Omari A, Tirupathi R, AlQahtani M, AlBahrani S, Dhama K. COVID-19 and mucormycosis superinfection: the perfect storm. Infection. 2021 Oct;49(5):833-853. doi: 10.1007/s15010-021-01670-1. Epub 2021 Jul 24. PMID: 34302291; PMCID: PMC8302461.
28. Kulkarni MD, Gulati S, Gupta S, Sabharwal R, Rajguru JP, Baneerjee A. Oral Mucormycosis: An Inevitable Complication of COVID-19. J Family Med Prim Care. 2022 May;11(5):1672-1676. doi: 10.4103/jfmpc.jfmpc_1599_21. Epub 2022 May 14. PMID: 35800548; PMCID: PMC9254828.
29. Shah NN, Khan Z, Ahad H, Elderdery AY, Alomary MN, Atwah B, Alhindi Z, Alsugoor MH, Elkhalifa AME, Nabi S, Bashir SM, Yaqub T, Rather GA, Ansari MA. Mucormycosis an added burden to Covid-19 Patients: An in-depth systematic review. J Infect Public Health. 2022 Nov;15(11):1299-1314. doi: 10.1016/j.jiph.2022.10.011. Epub 2022 Oct 14. PMID: 36279686; PMCID: PMC9562622.